GlassScriptPhysician profile
Kowsika Movva
NPI 1023490950
$3,623.33
in general payments reported to CMS, 2019-2025
35 companies · $906 in 2025
The $906 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,076 · 2020: $397 · 2022: $317 · 2023: $234 · 2024: $694 · 2025: $906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,834.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,833.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $568.40 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $471.56 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $295.68 | 2019-2024 | Prolia, Evenity, Repatha |
| Astrazeneca Pharmaceuticals LP | $230.07 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $213.76 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $197.01 | 2019-2020 | |
| Axsome Therapeutics, INC. | $178.99 | 2024-2025 | Auvelity |
| Mylan Specialty L.P. | $142.06 | 2019-2024 | Yupelri |
| Glaxosmithkline, LLC. | $140.55 | 2019-2025 | Trelegy Ellipta |
| Viiv Healthcare Company | $111.64 | 2025 | Apretude |
| Abbvie INC. | $107.38 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $96.40 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $92.60 | 2024-2025 | Rexulti, Abilify Maintena |
| Electromed, INC. | $91.32 | 2023-2025 | Smartvest |
| Amarin Pharma, INC. | $91.07 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $82.26 | 2019-2025 | Gardasil, Capvaxive, Gardasil 9 |
| Dexcom, INC. | $69.11 | 2022-2024 | Dexcom G6 Transmitter |
| Organon LLC | $42.13 | 2024-2025 | Nexplanon |
| Braeburn INC. | $41.57 | 2025 | Brixadi |
| Phathom Pharmaceuticals, INC. | $30.93 | 2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.84 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.89 | 2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $28.05 | 2019 | |
| Grifols USA, LLC | $24.93 | 2025 | Prolastin-C Liquid |
| Zyla Life Sciences, INC. | $23.89 | 2019-2020 | |
| Boston Scientific Corporation | $23.23 | 2025 | Watchman Access System |
| Optinose US, INC. | $21.97 | 2020 | |
| Lundbeck LLC | $21.55 | 2024 | Rexulti |
| Xeris Pharmaceuticals, INC. | $20.84 | 2023 | Gvoke Hypopen |
| Viatris Specialty LLC | $20.07 | 2025 | Yupelri |
| Allergan, INC. | $19.35 | 2020 | |
| Exact Sciences Corporation | $18.02 | 2025 | Cologuard Collection Kit |
| Insulet Corporation | $17.68 | 2024 | Omnipod |
| E.R. Squibb & Sons, L.L.C. | $14.69 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.84 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kowsika Movva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.